AbCellera Biologics (NASDAQ:ABCL – Get Rating) and MusclePharm (OTCMKTS:MSLP – Get Rating) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends.
Earnings and Valuation
This table compares AbCellera Biologics and MusclePharm’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|AbCellera Biologics||$375.20 million||10.80||$153.46 million||$0.79||17.92|
|MusclePharm||$50.04 million||0.07||-$12.87 million||($0.58)||-0.17|
AbCellera Biologics has higher revenue and earnings than MusclePharm. MusclePharm is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
This table compares AbCellera Biologics and MusclePharm’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Institutional & Insider Ownership
44.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 15.5% of MusclePharm shares are held by institutional investors. 30.3% of AbCellera Biologics shares are held by insiders. Comparatively, 60.7% of MusclePharm shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of current ratings for AbCellera Biologics and MusclePharm, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
AbCellera Biologics currently has a consensus target price of $28.50, suggesting a potential upside of 101.27%. Given AbCellera Biologics’ higher possible upside, equities analysts plainly believe AbCellera Biologics is more favorable than MusclePharm.
AbCellera Biologics beats MusclePharm on 11 of the 13 factors compared between the two stocks.
About AbCellera Biologics
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.